ArticleJournal of virology2017
Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 73 citations in OpenAlex.
- Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform.Biosafety and health · 2026Review
- Codon-Pair Deoptimized (CPD) Intranasal RSV Vaccines: A Novel Strategy for Infant Protection.International journal of molecular sciences · 2026Review
- The B cell receptor-mTOR signaling axis restricts the accumulation of lung tissue-resident memory B cells after influenza infection.Science immunology · 2026Article
- Monitoring of RSV-A and RSV-B Circulation in Poland Across Three Post-Pandemic Seasons (2022-2025).Viruses · 2026Article
- Respiratory Syncytial Virus F Protein Adjuvanted with a Carbomer-Based Adjuvant Induces Protective Humoral Response in Mice.ACS omega · 2026Article
- Article
- Molecular characterization of human respiratory syncytial virus in Mexico (season 2023-2024) through whole-genome sequencing.Scientific reports · 2025Article
- RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.Journal of virology · 2025Article
- Advances in development of antiviral strategies against respiratory syncytial virus.Acta pharmaceutica Sinica. B · 2025Review
- Polarization of the memory B-cell response.Journal of leukocyte biology · 2025Review
- Structures of respiratory syncytial virus G bound to broadly reactive antibodies provide insights into vaccine design.Scientific reports · 2025Article
- RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.bioRxiv : the preprint server for biology · 2025Article
- Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.Immunological reviews · 2024Review
- Antibody-mediated control mechanisms of viral infections.Immunological reviews · 2024Review
- Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction.NPJ vaccines · 2024Article
- Bovine Respiratory Syncytial Virus Nanovaccine Induces Long-Lasting Humoral Immunity in Mice.ACS pharmacology & translational science · 2024Article
- Virus neutralization assays for human respiratory syncytial virus using airway organoids.Cellular and molecular life sciences : CMLS · 2024Article
- Design and Preclinical Evaluation of a Nanoparticle Vaccine against Respiratory Syncytial Virus Based on the Attachment Protein G.Vaccines · 2024Article
- Serum and mucosal antibody-mediated protection and identification of asymptomatic respiratory syncytial virus infection in community-dwelling older adults in Europe.Frontiers in immunology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) causes severe respiratory disease in young children. Antibodies specific for the RSV prefusion F protein have guided RSV vaccine research, and in human serum, these antibodies contribute to >90% of the neutralization response; however, detailed insight into the composition of the human B cell repertoire against RSV is still largely unknown. In order to study the B cell repertoire of three healthy donors for specificity against RSV, CD27
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.